Dynamic Indium-111-Pentetreotide Scintigraphy in Breast Cancer

Journal of Nuclear Medicine

Volumn 37, Issue 4-6, 1996, Pages 622-626

  Bajc, Marika ^a   Ingvar, Christian ^a   Palmer, John ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Dynamic imaging; Indium 111 pentetreotide

Indexed keywords

DIAGNOSTIC AGENT; DRUG DERIVATIVE; ESTROGEN RECEPTOR; INDIUM; PENTETREOTIDE; PROGESTERONE RECEPTOR; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ARTICLE; BREAST TUMOR; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; FEMALE; HUMAN; LUNG CARCINOMA; MALE; MIDDLE AGED; PAGET NIPPLE DISEASE; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030116194     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. 123I-Thy)-pentetreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
2. Lamberts SWJ, Krenning EP, Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev 1991;12:450-482.
3. Lamberts SWJ, Reubi J-C. Kienning EP. Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors. J Steroid Biochem Molec Biol 1992;43:185-188.
4. Reubi JC, Waser B, Foekens JA, et al. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 1990;46:416-420.
5. Reubi JC, Laissue J, Krenning E, Lamberts SWJ. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Molec Biol 1992;43:27-35.
6. Reubi JC, Waser B, van Hagen M, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992;50:895-900.
7. Nesland, JM, Holm R, Johannessen JV, Gould VE. Neuroendocrine differentiation in breast lesions. Path Res Pract 1988;183:214-221.
8. Papotti M, Macri L, Bussolati G, Reubi JC. Correlative study on neuroendocrine differentiation and presence of somatostatin receptors in breast carcinomas Int J Cancer 1989;43:365-369.
9. van Eijck CHJ, Krenning EP, Bootsma A, et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994;343:640-643.
10. Foekens JA, Portengen H, van Putten WLJ, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin and epidermal growth factor in human breast cancer. Cancer Res 1989;49:7002-7009.
11. 111In DTPA-D-Phe-Octreotide in man assessed by whole-body scintigraphy Acta Radiol 1994;35:53-57.
12. Bajc M, Ingvar C, Persson B, et al. Dynamic octreotide scintigraphy in neuroendocrine tumours. Acta Radiol 1995;36:474-477.
13. Weber C, Merriam L, Koschitzky T, et al. Inhibition growth of human breast carcinomas in vivo by somatostatin analogue SMS 201-995: treatment of nude mouse xenografts. Surgery 1989;106:416-422.
14. Sepeshazy K, Milovanovic S, Lapis K, et al. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analogue of somatostatin, or a combination. Breast Cancer Res Treat 1992;21:181-192.